A detailed history of Earnest Partners LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Earnest Partners LLC holds 437 shares of LLY stock, worth $347,707. This represents 0.0% of its overall portfolio holdings.

Number of Shares
437
Previous 453 3.53%
Holding current value
$347,707
Previous $410,000 5.61%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$772.14 - $960.02 $12,354 - $15,360
-16 Reduced 3.53%
437 $387,000
Q1 2024

May 15, 2024

BUY
$592.2 - $792.28 $32,571 - $43,575
55 Added 13.82%
453 $352,000
Q3 2020

Nov 16, 2020

SELL
$146.22 - $169.13 $4,386 - $5,073
-30 Reduced 7.01%
398 $59,000
Q2 2019

Aug 13, 2019

SELL
$110.79 - $129.32 $4,099 - $4,784
-37 Reduced 7.96%
428 $47,000
Q4 2017

Feb 14, 2018

BUY
$81.94 - $87.89 $38,102 - $40,868
465
465 $39,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $756B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Earnest Partners LLC Portfolio

Follow Earnest Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Earnest Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Earnest Partners LLC with notifications on news.